We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Idera Pharmaceuticals Inc | NASDAQ:IDRA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.425 | 0.432 | 0.48 | 0 | 01:00:00 |
– Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 –– Cash runway into first quarter of 2020 –
“The third quarter of 2018 was marked by continued focus and execution throughout our company advancing the tilsotolimod ILLUMINATE 301 trial toward approval in our lead indication in anti-PD-1 refractory or relapsed metastatic melanoma. We also made significant progress framing our plans to expand the development of tilsotolimod to additional tumor types,” stated Vincent Milano, Idera’s Chief Executive Officer.
“Over these past several years, through all of the preclinical studies, translational data collections and ultimately our early clinical experiences, it’s becoming clearer to us that the potential utility of tilsotolimod is not limited to melanoma and is certainly not limited by the location or type of tumor,” continued Milano. “We look forward to providing our next clinical update from the ILLUMINATE 204 trial in the first half of December as well as laying out our expansion plans for the program in the beginning of 2019.”
“The majority of our company’s focus is and will remain towards maximizing the opportunity with, and more importantly, the number of patients that can benefit from, tilsotolimod. At the same time, we recognize and embrace the concept of continuing to build Idera for the future. To that end, we will continue to be aggressive in our pursuit of additional assets to further drive value for our shareholders, and more importantly, meet the needs of patients suffering from rare diseases with serious unmet needs.”
Clinical Development Program Updates:
ILLUMINATE (tilsotolimod) Clinical Development
ILLUMINATE 301 – Randomized Phase 3 trial of intratumoral tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with PD-1 refractory/relapsed metastatic melanoma:
ILLUMINATE 204 – Phase 1/2 trial of intratumoral tilsotolimod in combination with either ipilimumab or pembrolizumab in patients with PD-1 refractory/relapsed metastatic melanoma:
Ipilimumab Combination Arm – Phase 2 Recruitment Ongoing
Pembrolizumab Combination Arm – Phase 1 Dose Escalation Ongoing
ILLUMINATE 101 – Phase 1b trial of intratumoral tilsotolimod monotherapy in patients with refractory solid tumors:
Investigator Sponsored Trials (IST)Idera is supportive of several Investigator Sponsored Trials and continues to evaluate additional proposals:
Corporate Updates:During the quarter, the following Corporate Organizational Changes were announced:
Financial Results Third Quarter ResultsNet loss applicable to common stockholders for the three months ended September 30, 2018 was $11.6 million, or $0.43 per basic and diluted share, compared to net loss applicable to common stockholders of $14.5 million, or $0.78 per basic and diluted share, for the same period in 2017. Revenue in each of the three months ended September 30, 2018 and 2017 was nominal. Research and development expenses for the three months ended September 30, 2018 totaled $8.9 million compared to $10.9 million for the same period in 2017. General and administrative expense for the three months ended September 30, 2018 totaled $4.0 million compared to $3.9 million for the same period in 2017. Merger-related costs, net for the three months ended September 30, 2018 amounted to a net credit of $3.8 million and was comprised of a $6.0 million fixed expense reimbursement received in connection with the termination of the company’s proposed merger with BioCryst Pharmaceuticals, Inc., which was terminated in July 2018; partially offset by $2.2 million of expenses incurred in connection with the transactions contemplated by the related merger agreement. No such costs were incurred during 2017. Restructuring costs for the three months ended September 30, 2018 totaled $3.0 million and are a result of our decision in July 2018 to wind-down our discovery operations, reduce the workforce in Cambridge, Massachusetts that supported such operations, and close our Cambridge facility. No such costs were incurred during 2017.
As of September 30, 2018, the company’s cash and cash equivalents totaled $82.5 million. The company currently anticipates that, based on its current operating plan, its existing cash and cash equivalents will be sufficient to fund company operations into the first quarter of 2020.
About Idera PharmaceuticalsHarnessing the approach of the earliest researchers in immunotherapy and the Company’s vast experience in developing proprietary immunology platforms, Idera’s lead development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs. To learn more about Idera, visit www.iderapharma.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company’s strategy, future operations, collaborations, cash resources, financial position, future revenues, projected costs, prospects, clinical trials, plans and objectives of management, are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. There are a number of important factors that could cause Idera’s actual results to differ materially from those indicated or implied by its forward-looking statements, including whether the Company’s cash resources will be sufficient to fund the Company’s continuing operations and the further development of the Company’s programs for the period anticipated; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of the results that will be generated in future clinical trials; whether products based on the Company’s technology will advance into or through the clinical trial process when anticipated or at all or warrant submission for regulatory approval; whether such products will receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations will be successful; and such other important factors set forth under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the period ended December 31, 2017 and in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2018. Although Idera may elect to do so at some point in the future, the Company does not assume any obligation to update any forward-looking statements and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Idera Pharmaceuticals, Inc. Condensed Statements of Operations(In thousands, except per share data)
Three Months Ended | Nine Months Ended | ||||||||||||||||
September 30, | September 30, | ||||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||||
Alliance revenue | $ | 145 | $ | 164 | $ | 563 | $ | 729 | |||||||||
Operating expenses: | |||||||||||||||||
Research and development | 8,860 | 10,912 | 32,912 | 40,288 | |||||||||||||
General and administrative | 3,984 | 3,919 | 11,849 | 11,888 | |||||||||||||
Merger-related costs, net | (3,836 | ) | - | 1,245 | - | ||||||||||||
Restructuring costs | 3,017 | - | 3,017 | - | |||||||||||||
Total operating expenses | 12,025 | 14,831 | 49,023 | 52,176 | |||||||||||||
Loss from operations | (11,880 | ) | (14,667 | ) | (48,460 | ) | (51,447 | ) | |||||||||
Other income (expense), net | 275 | 137 | 729 | 389 | |||||||||||||
Net loss | $ | (11,605 | ) | $ | (14,530 | ) | $ | (47,731 | ) | $ | (51,058 | ) | |||||
Net loss per common share applicable to common stockholders — basic and diluted | $ | (0.43 | ) | $ | (0.78 | ) | $ | (1.81 | ) | $ | (2.73 | ) | |||||
Weighted-average number of common sharesused in computing net loss per share applicable tocommon stockholders — basic and diluted | 27,175 | 18,704 | 26,404 | 18,673 | |||||||||||||
Idera Pharmaceuticals, Inc.Condensed Balance Sheet Data(In thousands)
September 30, | December 31, | ||||||
2018 | 2017 | ||||||
Cash and cash equivalents | $ | 82,462 | $ | 112,629 | |||
Other assets | 2,768 | 5,788 | |||||
Total assets | $ | 85,230 | $ | 118,417 | |||
Total liabilities | $ | 10,364 | $ | 10,722 | |||
Total stockholders' equity | 74,866 | 107,695 | |||||
Total liabilities and stockholders' equity | $ | 85,230 | $ | 118,417 | |||
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals Contact:Robert A. Doody, Jr.VP, Investor Relations & CommunicationsPhone (484) 348-1677rdoody@iderapharma.com
1 Year Idera Pharmaceuticals Chart |
1 Month Idera Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions